EA201792304A1 - COMBINED THERAPY FOR CANCER TREATMENT - Google Patents

COMBINED THERAPY FOR CANCER TREATMENT

Info

Publication number
EA201792304A1
EA201792304A1 EA201792304A EA201792304A EA201792304A1 EA 201792304 A1 EA201792304 A1 EA 201792304A1 EA 201792304 A EA201792304 A EA 201792304A EA 201792304 A EA201792304 A EA 201792304A EA 201792304 A1 EA201792304 A1 EA 201792304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
combined therapy
inhibitors
human
cancer
Prior art date
Application number
EA201792304A
Other languages
Russian (ru)
Inventor
Хайке Кайльхак
Роберто Пили
Original Assignee
Эпизайм, Инк.
Хелт Рисерч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизайм, Инк., Хелт Рисерч, Инк. filed Critical Эпизайм, Инк.
Publication of EA201792304A1 publication Critical patent/EA201792304A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Настоящее раскрытие относится к композициям, содержащим ингибиторы метилтрансферазы гистонов EZH2 человека и одно или несколько других терапевтических средств (таких как ингибиторы тирозинкиназы или ингибиторы VEGF/VEGFR), в частности противораковые средства, такие как сунитиниб, а также к способам комбинированной терапии для введения субъектам, нуждающимся в этом, для лечения рака.The present disclosure relates to compositions containing inhibitors of human histone EZH2 methyltransferase human and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF / VEGFR inhibitors), in particular anti-cancer agents such as sunitinib, as well as combination therapy methods for administration to subjects needing it for cancer treatment.

EA201792304A 2015-04-20 2016-04-20 COMBINED THERAPY FOR CANCER TREATMENT EA201792304A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150185P 2015-04-20 2015-04-20
PCT/US2016/028425 WO2016172199A1 (en) 2015-04-20 2016-04-20 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
EA201792304A1 true EA201792304A1 (en) 2018-03-30

Family

ID=57143391

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792304A EA201792304A1 (en) 2015-04-20 2016-04-20 COMBINED THERAPY FOR CANCER TREATMENT

Country Status (11)

Country Link
US (3) US10456407B2 (en)
EP (1) EP3285773A4 (en)
JP (3) JP2018513865A (en)
CN (1) CN108135908A (en)
AU (3) AU2016252546A1 (en)
CA (1) CA2983265A1 (en)
EA (1) EA201792304A1 (en)
IL (1) IL255060A0 (en)
MX (1) MX2017013142A (en)
SG (2) SG11201708286PA (en)
WO (1) WO2016172199A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768555B (en) 2012-04-13 2018-10-30 Epizyme股份有限公司 Combination therapy for treating cancer
CN105873592B (en) 2013-12-06 2023-01-31 Epizyme股份有限公司 Combination therapy for the treatment of cancer
AU2016252546A1 (en) * 2015-04-20 2017-11-02 Epizyme, Inc. Combination therapy for treating cancer
JP6890097B2 (en) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド EZH2 inhibitor for treating lymphoma
SG10201909199PA (en) 2015-08-24 2019-11-28 Epizyme Inc Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
JP7121660B2 (en) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド Use of EZH2 inhibitors to treat cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
CN110191879A (en) * 2017-01-25 2019-08-30 恩瑞生物医药科技（上海）有限公司 A kind of histone methyltransferase EZH2 inhibitor, preparation method and its medical usage
US11642346B2 (en) * 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3678663A4 (en) * 2017-09-05 2021-06-02 Epizyme, Inc. Combination therapy for treating cancer
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US20220033813A1 (en) * 2018-09-11 2022-02-03 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
WO2021016409A1 (en) * 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
WO2021063340A1 (en) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Use of ezh2 inhibitor in combination with immune checkpoint inhibitor and tyrosine kinase inhibitor in preparation of medication for treating tumor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437451A (en) * 1890-09-30 Bee-swarm er
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
DK2614369T3 (en) 2010-09-10 2016-05-02 Epizyme Inc METHOD FOR DETERMINING THE SUITABILITY OF HUMAN EZH2 INHIBITORS TREATED
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TW201733984A (en) 2011-04-13 2017-10-01 雅酶股份有限公司 Substituted benzene compounds
RU2014117632A (en) 2011-09-30 2015-11-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи METHODS FOR TREATING A MALIGNANT TUMOR
CN104768555B (en) * 2012-04-13 2018-10-30 Epizyme股份有限公司 Combination therapy for treating cancer
PT2836491T (en) 2012-04-13 2017-02-08 Eisai R&D Man Co Ltd Salt form of a human histone methyltransferase ezh2 inhibitor
EP3628662A1 (en) 2012-10-15 2020-04-01 Epizyme, Inc. Substituted benzene compounds
EP2908823B1 (en) 2012-10-15 2019-09-25 Epizyme, Inc. Methods of treating cancer
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
RU2015139054A (en) * 2013-03-14 2017-04-19 Дженентек, Инк. METHODS FOR TREATING CANCER AND PREVENTION OF DRUG RESISTANCE OF CANCER
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc Substituted benzene compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
AU2014251028A1 (en) * 2013-04-08 2015-11-05 Janssen Pharmaceutica Nv Ibrutinib combination therapy
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
KR102142177B1 (en) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Hydrochloride salt form for ezh2 inhibition
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
CN105873592B (en) 2013-12-06 2023-01-31 Epizyme股份有限公司 Combination therapy for the treatment of cancer
KR102497728B1 (en) 2014-06-17 2023-02-09 에피자임, 인코포레이티드 Ezh2 inhibitors for treating lymphoma
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
BR112017007738B1 (en) 2014-10-16 2023-04-11 Epizyme, Inc METHOD FOR DETERMINING THE LIKELIHOOD OF EFFECTIVENESS OF A TREATMENT AND METHOD FOR SCREENING THE EFFECTIVENESS OF A TREATMENT COMPRISING AN EZH2 INHIBITOR
ES2947819T3 (en) 2014-11-17 2023-08-21 Epizyme Inc Method for cancer treatment with N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino )-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
AU2016252546A1 (en) * 2015-04-20 2017-11-02 Epizyme, Inc. Combination therapy for treating cancer

Also Published As

Publication number Publication date
IL255060A0 (en) 2017-12-31
EP3285773A1 (en) 2018-02-28
JP2018513865A (en) 2018-05-31
CN108135908A (en) 2018-06-08
CA2983265A1 (en) 2016-10-27
US20200101081A1 (en) 2020-04-02
MX2017013142A (en) 2019-03-28
SG10201902664RA (en) 2019-04-29
AU2016252546A1 (en) 2017-11-02
JP2023126957A (en) 2023-09-12
EP3285773A4 (en) 2019-04-10
US11026949B2 (en) 2021-06-08
US20180289717A1 (en) 2018-10-11
AU2023254894A1 (en) 2023-11-16
SG11201708286PA (en) 2017-11-29
AU2021204515A1 (en) 2021-07-29
US20210353632A1 (en) 2021-11-18
JP2021130700A (en) 2021-09-09
AU2021204515B2 (en) 2023-08-10
WO2016172199A1 (en) 2016-10-27
US10456407B2 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
EA201792304A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
EA201890009A1 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
EA201691079A1 (en) COMBINED THERAPY FOR THE TREATMENT OF ONCOLOGICAL DISEASE
CY1120866T1 (en) DNA-PK INHIBITORS
EA201990665A1 (en) HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER
EA201590855A1 (en) COMPOUNDS OF PYRROPOLYMIDININE AS KINAZ INHIBITORS
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA201792529A1 (en) Thyrosine Kinase Inhibitors
MX2019010601A (en) Combination therapy for treating cancer.
EA201690618A1 (en) BLUTON TYROSINKINASE INHIBITORS
MX2020010412A (en) Inhibitors of bruton's tyrosine kinase.
EA201391416A1 (en) NEW CONNECTIONS AS PROTEINKINASE MODULATORS
EA201691114A1 (en) BIARRYLIC CONNECTIONS USED IN THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEPHROLOGY AND IMMUNOLOGY
MX2017015574A (en) Inhibitors of bruton's tyrosine kinase.
EA201791516A1 (en) METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS
EA201790267A1 (en) NEW KINAZ MODULATORS
EA201791095A1 (en) CANCER TREATMENT METHOD
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201691032A1 (en) IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
EA201890567A1 (en) CANCER TREATMENT METHOD
TW201613577A (en) Pharmaceutical combinations
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION